Zevra Therapeutics, Inc. Revenue from Contract with Customer, Including Assessed Tax
Zevra Therapeutics, Inc. (ZVRA) reported Revenue from Contract with Customer, Including Assessed Tax of $39.66 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · last filed 2026-08-05
- Zevra Therapeutics, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2026-06-30 was $39.66M, a 53.25% increase year-over-year.
- Zevra Therapeutics, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2026-03-31 was $36.22M, a 77.54% increase year-over-year.
- Zevra Therapeutics, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2025-12-31 was $34.13M, a 183.36% increase year-over-year.
- Zevra Therapeutics, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2025-09-30 was $26.06M, a 605.36% increase year-over-year.
- Zevra Therapeutics, Inc. revenue from contract with customer, including assessed tax for fiscal 2025 was $106.47M, a 350.91% increase from fiscal 2024.
- Zevra Therapeutics, Inc. revenue from contract with customer, including assessed tax for fiscal 2024 was $23.61M, a 14.02% decline from fiscal 2023.
- Zevra Therapeutics, Inc. revenue from contract with customer, including assessed tax for fiscal 2023 was $27.46M, a 170.26% increase from fiscal 2022.
- Zevra Therapeutics, Inc. revenue from contract with customer, including assessed tax for fiscal 2022 was $10.16M, a 64.53% decline from fiscal 2021.
| Period end | Revenue from Contract with Customer, Including Assessed Tax 3 month | Revenue from Contract with Customer, Including Assessed Tax 3 month as first filed | Revenue from Contract with Customer, Including Assessed Tax 6 month | Revenue from Contract with Customer, Including Assessed Tax 6 month as first filed | Revenue from Contract with Customer, Including Assessed Tax 9 month | Revenue from Contract with Customer, Including Assessed Tax 9 month as first filed | Revenue from Contract with Customer, Including Assessed Tax 12 month | Revenue from Contract with Customer, Including Assessed Tax 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $39.66M 10-Q · filed 2026-08-05 | $75.88M 10-Q · filed 2026-08-05 | $110.01M derived: sum of 3 quarters · filed 2026-08-05 | $136.07M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | $36.22M 10-Q · filed 2026-05-06 | $70.34M derived: sum of 2 quarters · filed 2026-05-06 | $96.41M derived: sum of 3 quarters · filed 2026-05-06 | $122.29M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $34.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $60.19M derived: sum of 2 quarters · filed 2026-03-09 | $86.07M derived: sum of 3 quarters · filed 2026-08-05 | $106.47M 10-K · filed 2026-03-09 | ||||
| 2025-09-30 | $26.06M 10-Q · filed 2025-11-05 | $51.94M derived: sum of 2 quarters · filed 2026-08-05 | $72.34M 10-Q · filed 2025-11-05 | $84.39M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | $25.88M 10-Q · filed 2026-08-05 | $46.28M 10-Q · filed 2026-08-05 | $58.33M derived: sum of 3 quarters · filed 2026-08-05 | $62.02M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | $20.40M 10-Q · filed 2026-05-06 | $32.44M derived: sum of 2 quarters · filed 2026-05-06 | $36.14M derived: sum of 3 quarters · filed 2026-05-06 | $40.59M derived: sum of 4 quarters · filed 2026-05-06 | ||||
| 2024-12-31 | $12.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $15.74M derived: sum of 2 quarters · filed 2026-03-09 | $20.19M derived: sum of 3 quarters · filed 2026-03-09 | $23.61M 10-K · filed 2026-03-09 | ||||
| 2024-09-30 | $3.69M 10-Q · filed 2025-11-05 | $8.14M derived: sum of 2 quarters · filed 2025-11-05 | $11.57M 10-Q · filed 2025-11-05 | $24.49M derived: sum of 4 quarters · filed 2025-11-05 | ||||
| 2024-06-30 | $4.45M 10-Q · filed 2025-08-12 | $7.87M 10-Q · filed 2025-08-12 | $20.79M derived: sum of 3 quarters · filed 2025-08-12 | $23.69M derived: sum of 4 quarters · filed 2025-08-12 | ||||
| 2024-03-31 | $3.42M 10-Q · filed 2025-05-13 | $16.34M derived: sum of 2 quarters · filed 2025-05-13 | $19.24M derived: sum of 3 quarters · filed 2025-05-13 | $27.71M derived: sum of 4 quarters · filed 2025-05-13 | ||||
| 2023-12-31 | $12.92M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | $15.81M derived: sum of 2 quarters · filed 2025-03-12 | $24.29M derived: sum of 3 quarters · filed 2025-03-12 | $27.46M 10-K · filed 2025-03-12 | ||||
| 2023-09-30 | $2.90M 10-Q · filed 2024-11-13 | $11.37M derived: sum of 2 quarters · filed 2024-11-13 | $14.54M 10-Q · filed 2024-11-13 | $14.24M 10-Q · filed 2023-11-07 | $16.56M derived: sum of 4 quarters · filed 2024-11-13 | |||
| 2023-06-30 | $8.47M 10-Q · filed 2024-08-14 | $11.65M 10-Q · filed 2024-08-14 | $11.35M 10-Q · filed 2023-08-14 | $13.67M derived: sum of 3 quarters · filed 2024-08-14 | $16.54M derived: sum of 4 quarters · filed 2024-08-14 | |||
| 2023-03-31 | $3.18M 10-Q · filed 2024-05-09 | $2.88M 10-Q · filed 2023-05-15 | $5.20M derived: sum of 2 quarters · filed 2024-05-09 | $8.07M derived: sum of 3 quarters · filed 2024-05-09 | $9.37M derived: sum of 4 quarters · filed 2024-05-09 | |||
| 2022-12-31 | $2.02M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $4.90M derived: sum of 2 quarters · filed 2024-04-01 | $6.20M derived: sum of 3 quarters · filed 2024-04-01 | $10.16M 10-K · filed 2024-04-01 | $10.46M 10-K · filed 2023-03-07 | |||
| 2022-09-30 | $2.87M 10-Q · filed 2023-11-07 | $4.17M derived: sum of 2 quarters · filed 2023-11-07 | $8.14M 10-Q · filed 2023-11-07 | $10.72M derived: sum of 4 quarters · filed 2023-11-07 | ||||
| 2022-06-30 | $1.30M 10-Q · filed 2023-08-14 | $5.26M 10-Q · filed 2023-08-14 | $7.85M derived: sum of 3 quarters · filed 2023-08-14 | $9.81M derived: sum of 4 quarters · filed 2023-08-14 | ||||
| 2022-03-31 | $3.96M 10-Q · filed 2023-05-15 | $6.55M derived: sum of 2 quarters · filed 2023-05-15 | $8.51M derived: sum of 3 quarters · filed 2023-05-15 | $20.50M derived: sum of 4 quarters · filed 2023-05-15 | ||||
| 2021-12-31 | $2.58M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $4.55M derived: sum of 2 quarters · filed 2023-03-07 | $16.53M derived: sum of 3 quarters · filed 2023-03-07 | $28.65M 10-K · filed 2023-03-07 | ||||
| 2021-09-30 | $1.97M 10-Q · filed 2022-11-10 | $13.95M derived: sum of 2 quarters · filed 2022-11-10 | $26.07M 10-Q · filed 2022-11-10 | $28.43M derived: sum of 4 quarters · filed 2022-11-10 | ||||
| 2021-06-30 | $11.99M 10-Q · filed 2022-08-12 | $24.10M 10-Q · filed 2022-08-12 | $26.47M derived: sum of 3 quarters · filed 2022-08-12 | $28.39M derived: sum of 4 quarters · filed 2022-08-12 | ||||
| 2021-03-31 | $12.12M 10-Q · filed 2022-05-12 | $14.48M derived: sum of 2 quarters · filed 2022-05-12 | $16.41M derived: sum of 3 quarters · filed 2022-05-12 | $23.32M derived: sum of 4 quarters · filed 2022-05-12 | ||||
| 2020-12-31 | $2.37M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $4.29M derived: sum of 2 quarters · filed 2022-03-31 | $11.20M derived: sum of 3 quarters · filed 2022-03-31 | $13.29M 10-K · filed 2022-03-31 | ||||
| 2020-09-30 | $1.93M 10-Q · filed 2021-11-10 | $8.83M derived: sum of 2 quarters · filed 2021-11-10 | $10.92M 10-Q · filed 2021-11-10 | $12.30M derived: sum of 4 quarters · filed 2021-11-10 | ||||
| 2020-06-30 | $6.91M 10-Q · filed 2021-08-13 | $9.00M 10-Q · filed 2021-08-13 | $10.37M derived: sum of 3 quarters · filed 2021-08-13 | $21.84M derived: sum of 4 quarters · filed 2021-08-13 | ||||
| 2020-03-31 | $2.09M 10-Q · filed 2021-05-14 | $3.46M derived: sum of 2 quarters · filed 2021-05-14 | $14.93M derived: sum of 3 quarters · filed 2021-05-14 | |||||
| 2019-12-31 | $1.38M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | $12.84M derived: sum of 2 quarters · filed 2021-03-12 | $12.84M 10-K · filed 2021-03-12 | |||||
| 2019-09-30 | $11.46M 10-Q · filed 2020-10-30 | $11.46M 10-Q · filed 2020-10-30 | ||||||
| 2019-03-31 | $0.00 10-Q · filed 2020-05-13 | $0.00 derived: sum of 2 quarters · filed 2020-05-13 | $0.00 derived: sum of 3 quarters · filed 2020-05-13 | |||||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | $0.00 derived: sum of 2 quarters · filed 2020-02-28 | $0.00 10-K · filed 2020-02-28 | |||||
| 2018-09-30 | $0.00 10-Q · filed 2019-11-14 | $0.00 10-Q · filed 2019-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |